PhRMA speaks out against FDA biosimilar flexibility 30-Apr-2012 By Nick Taylor PhRMA has spoken out against FDA plans to allow biosimilar manufacturers flexibility in delivery device and formulation choice.
Amgen warns biosimilar draft a threat to production innovation 25-Apr-2012 By Nick TAYLOR Amgen has told the FDA that draft biosimilar guidance risks inhibiting manufacturing improvements and burdening industry.
